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I. Changes in the coagulation system in pregnant 
women
The blood coagulation involves the interaction of the 
vascular endothelium, platelets, plasmatic coagulation fac-
tors and consists of two stages: primary hemostasis (involves 
the vascular wall, vascular endothelium and platelets) and 
secondary hemostasis (activation of the coagulation cas-
cade). The vascular endothelium is the component of the 
vascular wall with an important hemostatic function at lo-
cal and systemic level through the secretion of substances 
with various actions (e.g. procoagulant, anticoagulant, fi-
brinolytic, antifibrinolytic, etc.), the molecular interactions 
of which favour coagulation in the subsequent stages and 
fibrinolysis.
Endothelial cells secret:
· Prothrombotic factors (tissue factor, von Willebrand 
(fvW) factor, plasminogen activator inhibitor (PAI 1 
and PAI 2), platelet activator factor (PAF), endothe-
lins, fibronectin, collagen);
· Antithrombotic factors: protein S, protein C, throm-
bomodulin, tissue factor pathway inhibitor (TFPI), 
heparan, antithrombin III, tissue plasminogen activa-
tor, urokinase, nitric oxide (NO), prostacyclin (PGI2);
· Vasodilating factors: prostacyclin (PGI2 ), NO;
· Vasoconstrictor factors: endothelins (ET-1, ET-2, 
ET-3).
The role of vasoactive substances (thromboxane (TX) 
and PGI2)) in maintaining hemostasis is their mutual an-
nihilating actions on thrombocyte functions (TX and PGI2 
counteract each other’s actions to maintain homeostasis 
with respect to platelet function). PGI2 inhibits platelet ag-
gregation and TX is a strong platelet aggregator and con-
tributes to the activation of other platelets. In addition, PGI2 
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Abstract
Background: The activity in the hemostasis system is determined by two opposite processes that function simultaneously – blood clotting (fibrin clot 
formation) and fibrinolysis (the process of fibrin clot breakage). A normal balance between the processes of coagulation and fibrinolysis produces 
neither coagulation nor lysis, and vice versa, the imbalance of these processes is potentially dangerous in the development of coagulopathic or lytic 
events.  Both systems (coagulation and fibrinolysis) undergo substantial changes in the physiological pregnancy, changes in an increase of coagulation 
factors concomitant with a decrease of anticoagulants and suppression in the fibrinolysis system. The predominance of prothrombotic activity gives 
the pregnancy a hypercoagulable status, with an increased risk of intravascular thrombi formation and thromboembolic complications (e.g. venous 
thrombosis, DIC syndrome). On the other hand, physiological hypercoagulation during pregnancy contributes to preventing the loss of blood during 
the immediate postpartum period by providing hemostasis in placental wounds and birth pathways. 
Conclusions:  The hemostasis system in pregnant women is marked by an increase in coagulation at each stage (from endothelium to circulatory factors 
of coagulation) which presumes the risk of thrombo-embolic complications, and the inhibition in the fibrinolytic system prevents peripartum bleeding.
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is a potent vasodilator and contributes to increased blood 
flow in the uthero-placental complex and TX has a vasocon-
strictor action. Endothelial dysfunction is accompanied by 
a reduction in PGI2 synthesis, and the platelet aggregation-
increasing TX effects and induction of vasoconstriction are 
determinant [1-3].
An important source of TX and PGI2 during pregnancy 
are placenta, placental vessel endothelium, umbilical cord 
and uterus; ductus arteriosus; derivatives of placenta – am-
nion, chorion and decidua. The healthy placenta produces 
an almost equal amount of TX and PGI2, that is why their 
biological action on vascular tone, platelet aggregation and 
uterine contractility is balanced. It should be mentioned 
that in physiological pregnancy the concentration of both 
substances increases – PGI2 (middle of pregnancy) and TX 
(towards the end of pregnancy). TX is primarily produced 
by trophoblast and stroma tissues, and PGI2 is the primary 
product of endothelial cells of placental vessels and in small-
er amounts of trophoblast (fig. 1). The increased serum 
concentration of TX derivatives and β-thromboglobulin 
(increased in the wall of the spiral arteries and in the inter-
villous space of the placenta) in the third trimester of preg-
nancy is further evidence of platelet activation.
In comparison with the physiological pregnancy in pre-
eclampsia TX production increases and PGI2 production 
decreases, so that the balance of the biological actions of 
these substances tend to favour TX actions. Decreased PGI2 
is also found in complicated pregnancies with intrauterine 
fetal development delay.
Another component of the coagulation system is plate-
lets. Generally the number of platelets does not change dur-
ing normal pregnancy (tab. 1), but it varies considerably 
within the normal baseline (50-70x109 /L) (tab. 1). Gesta-
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tional thrombocytopenia is defined as a reduction in plate-
lets below 150x109 /L determined in 5-12% of healthy preg-
nant women. Gestational thrombocytopenia occurs at an 
advanced gestational age (3rd trimester), rarely enough to 
have an impact on postpartum bleeding, and is secondary to 
the dilution effect in pregnancy when the plasmatic volume 
increases (at the end of the second trimester of pregnancy); 
reduction of platelets survival in pregnancy; increase in 
platelets breakage, etc. Restoration of normal platelets num-
ber occurs within the first 2 months after childbirth [4-6].
A peculiarity of the coagulopathic changes is related to 
platelet functions. The platelet membrane is composed of 
glycoproteins, phospholipids and cholesterol. Some glyco-
proteins act as membrane receptors (the most important 
complexes Ib-IX and IIb-IIIa). Transmembrane complex 
Ib-IX – role of thrombin receptor and von Willebrand fac-
tor in platelet adhesiveness. Complex IIb-IIIa – receptor for 
fibrinogen (essential in platelet aggregation) for Ca2+, von 
Willebrand factor.
Fig. 1.  Secretion distribution of vasoactive substances (PGI2, 
TX) by placenta in normotensive and with preeclampsia 
pregnant women.
Hemostatic functions of platelets:
1. Adhesion – the property of adhesion, their attachment 
to subendothelial structures (collagen, microfibrils, basal 
membrane). The adhesion process requires the presence of 
von Willebrand factor that binds the platelets to the suben-
dothelial structures.
2. Platelet activation – follows thrombocyte adhesion 
and consists in synthesis and release of thrombocyte factors 
and some active substances (histamine, serotonin, adrena-
line, immune complexes, PAF, arachidonic acid, TXA2, 
thrombin, etc.). All the released substances are designed to 
attract other platelets to the source, to activate them and de-
termine platelet aggregation and promote coagulation.
3. Aggregation – represents the property of platelets to 
join together to form conglomerates.
Increased adhesion, activation and aggregation of 
platelets is marked in complicated pregnancy induced by 
hypertension, preeclampsia, placental abruption, HELLP-
syndrome, prolonged retention of the dead fetus in utero, 
massive intra- and postpartum bleeding. Changes in adhe-
sion, activation and aggregation functions of platelets are de-
scribed differently in normotensive pregnant women [7, 8].
Von Willebrand factor as well as platelets is a compo-
nent of coagulation that occurs at the primary hemosta-
sis stage. FvW is the vascular (endothelial) component of 
the coagulation system and has a mediator function in the 
platelet adhesion process to endothelial injured structures. 
In addition, it is the transporting protein of VIII factor. The 
fvW level increases progressively during the physiological 
pregnancy (tab. 1). A parallel increase of fVIII is marked 
out. The increase in fvW far exceeds its normal level from 
a normal pregnancy in obstetric complications, the appear-
ance and development of which are attributed to endothelial 
dysfunction (e.g. from preeclampsia) [9].
Essential changes in the blood coagulation system in 
pregnant women are determined by an increase of coagu-
lation factors and a concomitant decrease of inhibitors of 
blood coagulation (anticoagulants). Factors with direct con-
tribution to blood hypercoagulability (with the exception of 
XI and XIII factors) during pregnancy are: fI (fibrinogen); 
fVII (proconvertin); fVIII (antihemophilic A factor circu-
lating in plasma associated with von Willebrand factor); fX 
(Stuart-Prower factor); fXII (Hageman factor); fvW (von 
Willebrand) (tab.1). The IX (antihemophilic B factor or 
Christmas factor), II (prothrombin), and V (proaccelerin) 
factors increase insignificantly or remain unchanged (tab. 
1) [2, 6, 9, 10]. The high serum concentration of coagulation 
factors is reflected on the diagnostic parameters of blood 
coagulation during pregnancy, marked by shortening of 
coagulation time; shortening of PT and aPTT (sometimes 
below lower reference limits); increase of thrombo-elasto-
graphic parameters such as maximum clot firmness (MCF) 
and maximum amplitude (MA) [4, 11-14].
The serum level of fibrinogen in pregnancy at term con-
stitutes (4–6  g/l) (tab.1), a double exceeding as against its 
reference values outside the pregnancy (2-4 g/L). Thus, the 
fibrinogen level considered normal for non-pregnant status 
– 2 g/l, in postpartum bleeding (hypo-atonic) may indicate 
the loss of a significant amount of blood [1, 15-17].
Increased formation of thrombin-antithrombin com-
plexes (TAT), prothrombin fragments 1 and 2 in the second 
and third trimester of pregnancy is another indicator of hy-
percoagulability in pregnant women. The TAT complex is 
formed as a result of the interaction of these factors; it is a 
non-active complex, the formation of which is followed by 
the loss of activity of both components, thrombin and anti-
thrombin. The presence of serum complexes TAT is a mark-
er of increased thrombin formation and their progressive 
increase may indicate a possible depletion of antithrombin. 
Prothrombin fragments 1+2 (FP1+2), as well as TAT com-
plexes, are indicators of thrombin formation. FP1+2 frag-
ments are generated during prothrombin transformation 
into thrombin (tab. 1) [3, 18-20].
With the evolution of pregnancy the fibrinopeptid A 
concentration increases. Fibrinopeptid A is a marker of fi-
brin formation. Under the proteolytic action of thrombin 
the fibrinogen is cleaved into fibrinopeptids A, B and fibrin 
monomers. The serum level of fibrinopeptid A is maximal 
in the last trimester of pregnancy, the increase of which in 
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plasma indicates increased formation of thrombin and fi-
brin generation in physiological pregnancy (tab. 1).
Table 1
Changes of hemostasis system in pregnancy
Physiological components
of blood
Out of 
pregnancy In pregnancy
Platelets 150-350x109
Unchanged
Von Willebrand (fvW) factor 100% Increases
Fibrinogen (fI) 2.0-4.5 g/l 4.0-6.5 g/l
F II (prothrombin) 75-125% 100-125%
F V (proaccelerin) 75-125% 100-150%
F VII (proconvertin) 75-125% 150-250%
F VIII (antihemophilicA 
factor)
75-150% 200-500%
F IX (antihemophilic B factor 
or Christmas factor)
75-125% 100-150%
F X (Stuart-Prower factor) 75-125% 150-250%
F XI, antihemophilic globu-
lin C (Rosenthal factor )
Does not change
F XII (Hageman factor) 75-125% 100-200%
F XIII (fibrin stabilizing 
factor)
75-125% 35-75%
Prekallikrein Does not change
Kininogen with high mo-
lecular weight
Does not change
Protein S 100% Decreases(↓)
Protein C 100%
Does not change/
increases resistance to 
protein C
Antithrombin III 80-130% Does not change
Heparin cofactor II Increases
Complexes TAT Increase
Fragment 1  of prothrombin Increases
Fragment 2 of  prothrombin Increases
Fibrinopeptid A Increases
Complexes PAP Increase
Tissue plasminogen 
activator(t-PA)
1.6-13µg/l 3.3-9.2 µg/l  (↓)
TAFI Increases
Inhibitors of plasminogen 
activator (PAI-1, PAI-2)
100% Increase
Thrombomodulin Increases
Fibrin degradation products 
(FDP)
Increase
D-dimers <0.5 mg/l 0.13-1.7 mg/l
There are a number of factors with inhibitory action on 
blood coagulation preventing in such a way the formation of 
thrombi.  Some of the important physiological inhibitors are 
antithrombin, protein C, protein S, heparin cofactor II, tis-
sue factor pathway inhibitor or coagulation extrinsic path-
way inhibitor (TFPI).  Hypercoagulability during pregnancy 
is favoured/supported by changes of anticoagulants marked 
by a significant reduction (40-50% decrease in protein S) or 
neutrality (e.g. antithrombin, protein C, which remain un-
changed). Antithrombin III  –  powerful  inhibitor of blood 
coagulation by inactivating most enzymes: thrombin (f II), 
fIX (antihemophilic B or Christmas factor), fX (Stuart-
Prower), f XI, fXII (Hageman factor), and of VIIa complex 
factor and tissue factor.
Protein S is an anticoagulant that works in association 
with protein C. The decrease of protein S during pregnancy 
reduces the amount of thrombomodulin-thrombin-protein 
C and S complexes formation, thus diminishing their in-
hibitory action on V and VIII factors with increased pro-
coagulant activity of the blood. In pregnancy the level of 
thrombomodulin increases [2, 21-23].  
Out of pregnancy the interaction of the mentioned an-
ticoagulants works differently. At the endothelial cells level 
thrombomodulin binds thrombin. The formed complex 
activates the protein C which in the presence of proteins S 
and Ca2+ leads to a decrease in blood coagulation through 
activation of factors V and VIII.
One of the important mediators of blood coagulation is 
the tissue factor (TF). In pregnancy a substantial increase 
in tissue factor concentration in decidua, myometrium, pla-
centa, fetal membranes (especially in amnion) and amniotic 
fluid is determined. Inhibition of TF activation is accom-
plished by the tissue factor pathway inhibitor (TFPI) which 
has anticoagulant impact, the placenta being an important 
source of TFPI production and release in the maternal cir-
culation. Thus, the concentration of TFPI increases signifi-
cantly and progressively in the physiological pregnancy, the 
maximal level of which is reached in the pregnancy at term, 
with a dramatic decrease close to the non-pregnant level in 
the first postpartum day [1, 20, 21, 24].
II. Fibrinolysis and fibrinolytic activity in pregnancy
Fibrinolysis is a mechanism of prevention of thrombo-
sis, consisting of a set of reactions that lead to fibrin degra-
dation with a repermeabilization of the injured vessels and 
resumption of blood circulation. Plasmin is the enzymat-
ic key of fibrinolysis that plays the role of thrombus lysis. 
The plasmin is formed from the activated plasminogen (in 
circulation the plasminogen is inactive). The activation of 
plasminogen (under the influence of fibrinolysis activators) 
is accompanied by its transformation into plasmin, and the 
plasmin acting on fibrin degrades it into fragments until fi-
nal products are formed (fig. 2).
Plasmin is inactivated by antiplasmins (inhibitors of 
fibrinolysis with action on plasmin) –  α2-antiplasmin and 
α2–macroglobulin (fig. 2), with the formation of plasmin-
antiplasmin complexes (PAP), the concentration of which 
increases in the physiological pregnancy. The increased PAP 
complexes concentration during pregnancy is also due to 
the increase in antiplasmins. Plasmin in the formed com-
plexes (PAP) loses the ability to destroy the fibrin.
Fibrin degradation product (FDP) increases progres-
sively in pregnancy through increased formation of fibrin 
and secondary enhancement of fibrinolysis. Excessive pro-
duction of FDP (e.g. in obstetrical complications that in-
volve coagulation system activation, preeclampsia, abrup-
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tion placentae, DIC syndrome, etc.) has an anticoagulation 
impact and inhibits blood coagulation [5, 25].
A more specific indicator for the fibrinolysis process than 
FDP is D-dimers. The level of D-dimers begins to gradually 
increase from the 1st trimester of pregnancy, so that at the 
end of pregnancy its levels may be 3-4 times higher than the 
initial level. Significant increase in D-dimers is determined 
in pregnant women with complications of pregnancy (e.g. 
DIC syndrome, thrombosis of deep veins, thromboembolic 
complications in pregnancy, etc.) (tab. 1). Excess concentra-
tion of D-dimers in such complications indicates activation 
of fibrinolysis preceded by the activation of coagulation cas-
cade with excessive fibrin formation.
D-dimers and PAP complexes are markers of the fibri-
nolysis process. Thus, hemostasis markers change during 
pregnancy, reflecting the increase in thrombin generation 
(fragment 1 and 2 of prothrombin, TAT complexes, fibri-
nopeptid A) on the one hand, and increase of fibrinolysis 
(D-dimers, PAP complexes) on the other hand [21, 26-28].
Similar to the coagulation system, the fibrinolytic pro-
cess is the result of the interaction of activators and inhibi-
tors. At the action of fibrinolitic activators the endovascular 
deposits of fibrin are removed, but the inhibitors prevent 
premature lysis of the hemostatic thrombus that could lead 
to a prolonged bleeding. The fibrinolysis can be activated in 
two ways – extrinsic and intrinsic [10, 11, 23, 24].
The activators of extrinsic fibrinolysis are tissue plas-
minogen activator (t – PA); U – PA urokinase and activators 
of bacterial origin (streptokinase, staphylokinase, proteo-
lytic enzymes, e.g. trypsin). The activation of intrinsic fibri-
nolysis is triggered by f XII (Hageman), kallikrein. The final 
effects of the activators of both pathways of fibrinolysis are 
unanimous, to transform the plasminogen into plasmin.
The fibrinolysis inhibitors act upon the enzymes (plas-
minogen and plasmin) involved in the most important fibri-
nolysis reactions: 1. The inhibitors of the tissue activator of 
plasminogen (t-PA) impede in such a way the transforma-
tion of plasminogen into plasmin; 2. Inhibitors with direct 
action on the plasmin (the effect of stopping the thrombus 
lysis) (fig. 2).
The fibrinolysis inhibitors to neutralize the tissue activa-
tor of plasminogen are collectively called PAI (plazminogen 
activator inhibitors): PAI-1 – produced by endothelial cells, 
platelets, hepatocytes and stimulated by proinflammatory 
cytokines; PAI-2 – is met exclusively in pregnant women, 
produced by the cells of chorionic villosities, progressively 
increases in pregnancy, returning to normal values 6 weeks 
after childbirth; PAI-3 – a powerful inhibitor of protein C.
Both substances, PAI -1 and PAI-2, can inhibit the ac-
tivators of the intrinsec pathway of fibrinolysis (t-PA and 
U-PA).
The inhibitors with direct action on the plasmin are α2– 
antiplazmin, α2 macroglobulin, α1 antitrypsin. The fibrinoly-
sis inhibitor activated by the thrombin TAFI. TAFI modifies 
fibrin filaments, inhibiting the binding of plasminogen to 
the fibrin network and implicitly its activation to plasmin;
The activity of the fibrinolysis system is opposed to the 
activity of coagulation system, marked by the decrease in 
activators and increase in inhibitors, with subsequent sup-
pression in the fibrinolytic system in pregnancy.
Changes in fibrinolysis activators during pregnancy:
· Plasminogen increases but its fibrinolytic activity de-
creases;
· Decrease in tissue plasminogen activator (t-PA) due to 
the increase of the levels of inhibitors of plasminogen 
activators during pregnancy – PAI-1 and PAI-2.
Changes in coagulation inhibitors in pregnancy:
· Increase in inhibitors of plasminogen activator – PAI-
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1 and PAI-2. In particular, the inhibition of fibrinolysis 
in pregnancy is due to the increase of inhibitor of type 
2 (PAI-2) of the plasminogen activator.
· Significant increase of inhibitors with direct action 
on plasmin – α2 antiplazmin; α2 – macroglobulin, α1-
antitrypsin. 
· Increase of the fibrinolysis inhibitor, activated by the 
thrombin – TAFI.  TAFI reaches maximal values up 
to 35-39 SA with a rapid decrease in 24 hours after 
childbirth.
Conclusions
The hemostasis system in pregnant women is marked by 
an increase in coagulation at each stage (from endothelium 
to circulatory factors of coagulation) which presumes the 
risk of thrombo-embolic complications, and the inhibition 
in the fibrinolytic system prevents peripartum bleeding.
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